Clinical Trial Update: Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Dysport (abobotulinumtoxinA) for urinary incontinence due to neurogenic detrusor overactivity in adults with spinal cord injury or mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity
• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Ipsen | Conditions: Urinary Incontinence, Overactive Bladder | Phase 3 | Status: TERMINATED | Results posted: 2021-06-16